Selecting here opens the current stored cards. The pinned link below records their fingerprints. Do not enter patient information in links or searches.
Share or print this source review
1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.
Copy is optional; the link can be selected and copied manually. No patient data or dose decision is collected.
Clinical context remains essential
Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.
The original page contains two different IV renal band sets (25/50 versus 30/50) and an indexed CrCl table. They are preserved separately, not reconciled into one recommendation. Confirm the applicable current product label before clinical use.
Check source scope before reading a dose
UCSF - oral acyclovir: HSV and VZV
Product / population
Adults; oral acyclovir only.
Renal method
CrCl in mL/min where specified; no equation inferred.
Source revision
Revision date not stated in the reviewed page.
Retrieved
2026-09-05
Local review status
Locally included source-specific summary. Regimen differences are not automatically resolved.
UCSF Infectious Diseases Management Program · Adults; oral acyclovir only.
Renal method: CrCl in mL/min where specified; no equation inferred. Source date: Revision date not stated in the reviewed page. Retrieved: 2026-09-05
Locally included source-specific summary. Regimen differences are not automatically resolved.
Dosing / renal protocol and limits
Limits that apply to these rows
Dialysis recommendations use limited data and expert opinion. The source advises considering an additional post-HD dose. Oral and IV protocols are not interchangeable.
Initial HSV - oral
CrCl, mL/min
Source-specific dose / instruction
>25
400 mg every 8 hours
10-25
400 mg every 8 hours
<10
200 mg every 12 hours
Mild VZV - oral
CrCl, mL/min
Source-specific dose / instruction
>25
800 mg five times daily
10-25
800 mg every 8 hours
<10
400 mg every 12 hours
Dialysis guidance - separate source-specific schedules
Oral acyclovir - dialysis
Dialysis setting / indication
Source-specific schedule
Intermittent HD - initial/recurrent HSV
200 mg every 12 hours
Intermittent HD - VZV
400 mg every 12 hours
Intermittent HD - suppression/prophylaxis
200 mg every 12 hours
Continuous HD - initial HSV
400 mg every 8 hours
Continuous HD - recurrent HSV or prophylaxis
400 mg every 12 hours
Continuous HD - VZV
800 mg five times daily
Read the retained text before reformatting
CrCl >25 / 10-25 / <10 mL/min: initial HSV uses 400 mg orally every 8 hours / 400 mg every 8 hours / 200 mg every 12 hours. Mild VZV uses 800 mg five times daily / 800 mg every 8 hours / 400 mg every 12 hours.
Intermittent HD: initial or recurrent HSV 200 mg every 12 hours; VZV 400 mg every 12 hours; suppression/prophylaxis 200 mg every 12 hours. Continuous HD: initial HSV 400 mg every 8 hours; recurrent HSV 400 mg every 12 hours; VZV 800 mg five times daily; prophylaxis 400 mg every 12 hours.
Dialysis recommendations are based on limited data and expert opinion. The page advises consideration of an additional post-HD dose. Do not transfer these oral regimens to IV acyclovir.
RDM30-034-acyclovir-1 · Source locator: UCSF - oral acyclovir: HSV and VZV; renal/dosing sections and stated qualifiers
This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.
GlobalRPh v6.6 | RDM66-DIRECT-PHP-20260911 | Local library date 2026-09-11. Selected-card identity does not imply clinical verification.